Loading...
XSTO
NXTCL
Market cap8mUSD
Dec 05, Last price  
0.74SEK
1D
-0.14%
1Q
-31.94%
IPO
-78.34%
Name

NextCell Pharma AB

Chart & Performance

D1W1MN
XSTO:NXTCL chart
P/E
P/S
7.68
EPS
Div Yield, %
Shrs. gr., 5y
36.08%
Rev. gr., 5y
42.54%
Revenues
11m
+5.45%
6,960809,006517,203655,4131,812,1713,564,7013,912,0175,588,79710,113,47410,664,701
Net income
-42m
L+5.40%
-10,289,715-11,413,381-13,245,206-14,032,294-21,458,571-17,689,535-24,564,328-34,084,746-39,811,631-41,959,818
CFO
-38m
L-13.80%
-7,761,554-11,119,038-14,815,788-13,549,779-22,134,553-18,959,872-25,577,128-33,311,720-43,825,695-37,778,383

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

NextCell Pharma AB, a biopharmaceutical company, engages in the research and development of novel stem cell therapies in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases. It also provides Cellaviva, a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. NextCell Pharma AB was incorporated in 2014 and is based in Huddinge, Sweden.
IPO date
Jul 13, 2017
Employees
15
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑082023‑082022‑082021‑082020‑082019‑082018‑082017‑082016‑08
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT